An experimental drug regimen for breast cancer being developed by Relay Therapeutics delayed tumor growth by a median of about nine months in a small clinical trial, results that were promising enough ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eli Lilly has turned to a biotechnology startup for ...

Ensem Therapeutics, Inc, a pioneering drug discovery and development company to leverage its unique kinetic ensemble platform to advance innovative small molecule precision medicines for oncology, ...

(RTTNews) - Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor program STX-478 for up to $2.5 billion in cash. STX-478 ...

Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer treatment program in a deal worth up to $2.5 billion. The Indianapolis-based ...

BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose ...

PI3Kα inhibitors are approved to treat certain cancers with PIK3CA mutations, but resistance often develops during treatment. Researchers have now identified additional cancer mutations that arise to ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...